Compare MCHB & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCHB | ARQT |
|---|---|---|
| Founded | 1905 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.3B |
| IPO Year | N/A | 2020 |
| Metric | MCHB | ARQT |
|---|---|---|
| Price | $14.27 | $22.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $14.50 | ★ $34.00 |
| AVG Volume (30 Days) | 335.6K | ★ 1.2M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | ★ 11.33% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $36.61 | $34.46 |
| Revenue Next Year | $5.40 | $29.77 |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $12.82 | $11.86 |
| 52 Week High | $16.02 | $31.77 |
| Indicator | MCHB | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 39.50 |
| Support Level | $13.89 | $22.56 |
| Resistance Level | $15.65 | $27.26 |
| Average True Range (ATR) | 0.48 | 0.96 |
| MACD | -0.04 | -0.17 |
| Stochastic Oscillator | 32.02 | 26.06 |
Mechanics Bancorp is an independent, full-service community bank. It provides personal banking, business banking, trust and estate, brokerage and wealth management services. its retail banking products include personal checking, savings, and loan products (including credit card, home equity, home mortgage, and secured/unsecured loans), online banking, and wealth management services (including trust and estate, investment management, and financial planning services). its banking products and services for businesses include business checking and savings accounts, business debit cards, online banking, cash management services, wealth management services, business credit cards, commercial real estate loans, equipment leasing, and loans guaranteed by the Small Business Administration.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.